Cointime

Pretzel Therapeutics

company

About

Pretzel Therapeutics mission is to develop groundbreaking therapies to reverse mitochondrial dysfunction through mitochondrial biology.

  • 11 - 50

Highlights

Total Funding Amount
$72.50M
Funding Rounds
2
Investors
2

Details

Last Funding Type
Series A
Last Funding Money Raised
$72.50M
Industries
Biotechnology,Pharmaceutical,Therapeutics
Founded date
Jan 1, 2019
Number Of Employee
11 - 50
Operating Status
Active

Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation.

Our name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinating features that make it unlike any other organelle in the body.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$72.50M
Pretzel Therapeutics has raised a total of $72.50M in funding over 2 rounds. Their latest funding was raised on Sep 12, 2022 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 12, 2022 Series A $72.50M 2 ARCH Venture Partners — Detail
Oct 10, 2021 Series Unknown — 1 Cambridge Innovation Capital — Detail

Investors

Number of Lead Investors
Number of Investors
2
2
Pretzel Therapeutics is funded by 2 investors. ARCH Venture Partners and Cambridge Innovation Capital are the most recent investors.
Investor Name Lead Investor Funding Round
ARCH Venture Partners Yes Series A
Cambridge Innovation Capital — Series A
Cointime
เนื้อหา
บริษัท